A study to compare macitentan versus macitentan in patients with Pulmonary Arterial Hypertension (H-47077)

A phase 3, prospective, multicenter, double-blind, double-dummy, randomized, active controlled, parallel-group, group-sequential, adaptive, event- driven study to compare efficacy, safety, and tolerability of macitentan 75 mg versus macitentan 10 mg in patients with Pulmonary Arterial Hypertension, followed by an open-label treatment period with macitentan 75 mg.